Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.

Article Details

Citation

Copy to clipboard

Steinfeld SD, Youinou P

Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.

Expert Opin Biol Ther. 2006 Sep;6(9):943-9.

PubMed ID

16918261 [ View in PubMed

]

Abstract

B cells play an important role in the pathogenesis of many autoimmune diseases. Different approaches targeting the B cell compartment are under investigation. Selective modulation of B cells has been recently achieved using a humanised monoclonal antibody against the B cell surface marker CD22. This antibody (epratuzumab) was originally developed for the treatment of non-Hodgkin's lymphoma and was found to be effective, with a very good safety profile. Recent studies have demonstrated the efficacy and safety of epratuzumab in several autoimmune diseases, including systemic lupus erythematosus and primary Sjogren's syndrome.

DrugBank Data that Cites this Article

Drugs

Epratuzumab

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Epratuzumab	B-cell receptor CD22	Protein	Humans	Yes	Antibody Regulator	Details